The migraine research of the past 30 years has contributed significantly to elucidate the emergence of migraine attacks. This includes the discovery of a first migraine gene in 1993 and the discovery of a second one in 2003. These research results could also refute the old theory that the neurological deficits of the migraine aura (esp. Visual and sense disturbances in the run-up to the attack) by a narrowing of cerebral arteries come about and the headache caused by the expansion of the brain and cranial arteries. Today we know that a migraine develops in the brain, more precisely in the brainstem, as a derailment of quite normal regulatory circuits that control functions such as alertness, hunger and thirst. Damage does not result.
We carry out drug studies and migraine researches in our international research centre to ensure our up to date knowledge and to offer improved treatment options. In addition, the Kopfwehzentrum Hirslanden AG regularly participates in national and international studies as an official study centre in cooperation with Neurologica GmbH. We furthermore participate in studies all over the world.
Participation in studies
We’re always looking for suitable study participants for our studies (migraines, cluster headaches, ect.).
Who can participate in a study?
In order to participate in a study at the Kopfwehzentrum Hirslanden AG, a previous visit to one of our doctors is necessary. It will determine if and on which study participation is possible. Each study has inclusion and exclusion criteria, all of them must be met for a person to be allowed to participate in this study. The criteria may include the gender, age or previous treatments and so on.
Information and registration
For further information and to register for participation in our studies, please contact our study coordinators, Miss Karin Doering and Miss Lea Aeschlimann, via e-mail firstname.lastname@example.org or phone call +41 (0) 43 499 13 30.
General Consult: Further use of your data and samples for research purposes
Detection and treatment of diseases has made a great progress in recent years, in particular because of the medical research. Kopfwehzentrum Hirslanden AG is committed to ensure the gather of new insights which help understand and treat diseases better. To do this research, doctors need health data and biological samples from healthy and sick people.
However, in accordance with Swiss law, we may only use patient data and their samples if we have your written consent. During your first appointment at Kopfwehzentrum Hirslanden AG you will be asked if you are willing to provide your data for our research. You will receive an information sheet with the declaration of consent (General Consult) which you must sign.
Download the information sheet here:
© Janine Heers